DFDA

Lenvatinib

Treatment for Liver Cancer Due To Hepatitis C

Typical Dosage: 8 mg or 12 mg orally once daily

Effectiveness
75%
Safety Score
50%
Clinical Trials
30
Participants
8K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
8 mg or 12 mg orally once daily
Time to Effect
1-2 months
Treatment Duration
Until disease progression or unacceptable toxicity
Evidence Quality
HIGH
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$175,000
Monitoring:$7,500
Side Effect Mgmt:$5,000
Total Annual:$187,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$120,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$778,008
Comparison vs Sorafenib
Cost Difference
+$40,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Lenvatinib Outcomes

for Liver Cancer Due To Hepatitis C

Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+24.1%
Common Side Effects
Hypertension
+45%
Fatigue
+35%
Diarrhea
+35%
Decreased appetite
+30%
Proteinuria
+20%

Sources:

mdpi.com
targetedonc.com
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov